SGLT-2抑制剂和GLP-1受体激动剂的联合使用_替代终点和硬终点的潜在好处.pdf,1879 Send Orders for Reprints to reprints@benthamscience.ae Current Pharmaceutical Design, 2018, 24, 1879-1886 REVIEW ARTICLE Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agoni
the cellular mechanisms associated with CV protection afforded by these agents, investigating a pleiotropic range of potential effects to improve bone marrow (BM), kidney, heart, and vascular health. Additionally, there is gr...
持续葡萄糖监测(CGM)能提供连续、全面、可靠的血糖情况,发现不易被传统监测方法所探测到的隐匿性高血糖和低血糖,同时提供 TIR 等信息,过去常用于胰岛素治疗的 1 型或 2 型糖尿病(T1DM/T2DM)患者的血糖监测[4]。而胰高糖素样肽-1 受体激动剂(GLP-1RA)和钠-葡萄糖共转运蛋白 2 抑制剂(SGLT2i)等控糖新药,...
持续葡萄糖监测(CGM)能提供连续、全面、可靠的血糖情况,发现不易被传统监测方法所探测到的隐匿性高血糖和低血糖,同时提供 TIR 等信息,过去常用于胰岛素治疗的 1 型或 2 型糖尿病(T1DM/T2DM)患者的血糖监测[4]。而胰高糖素样肽-1...
SGLT-2i plus GLP-1RA therapy was generally well tolerated, with a low risk of hypoglycemia and no unexpected findings. Taken together with results from large CV outcomes trials of SGLT-2is and GLP-1RAs, combination therapy with these agents potentially provides effective durable glycemic control ...
2iplusGLP-1RAtherapyversustheindividualagentsorbaseline.SeveralCVriskfactors,includingbodyweight,bloodpressure,andlipidparameters,werealsoimproved.SGLT-2iplusGLP-1RAtherapywasgenerallywelltolerated,withalowriskofhypoglycemiaandnounexpectedfindings.TakentogetherwithresultsfromlargeCVoutcomestrialsofSGLT-2isandGLP-1RAs,...
The evidence for cardiovascular benefit of SGLT2i and GLP1RA has rightfully prompted the diabetes and cardiovascular communities to incorporate these new classes of agents into clinical management guidance. Biguanides Metformin has remained first-line treatment for T2DM due to its efficacy, safety, ...
and GLP-1 RA therapy initiation in eligible patients with cardiorenal risk; importantly, we note that this clinical inertia is contrary to a wealth of evidence from CVOTs, and despite updates to clinical guidelines that encourage SGLT2i and GLP-1 RA use. We also find that low uptake of ...
which has the potential to stimulate secretion of GLP-1, in addition to inhibition of glucose reabsorption in the kidney.53 LX4211 has completed a Phase IIb trial in type 2 diabetics and is currently undergo- ing a proof-of-concept study in type 2 diabetes with renal impairment and one in...
Combination therapy in patients with DM may be considered with agents, including glucagon-like peptide-1 receptor agonists (GLP-1-RAs), novel mineralocorticoid receptor antagonists, and selective endothelin receptor antagonists to reduce residual albuminuria and cardiovascular risk....